Cargando…
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
Dysregulation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin signaling is common in both indolent and aggressive forms of malignant lymphoma, for which several targeted therapies have been developed. Copanlisib is a highly selective and potent intravenous pan-...
Autores principales: | Munoz, Javier, Follows, George A., Nastoupil, Loretta J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941125/ https://www.ncbi.nlm.nih.gov/pubmed/33687623 http://dx.doi.org/10.1007/s11523-021-00802-9 |
Ejemplares similares
-
Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic
por: Chauhan, Ayushi F, et al.
Publicado: (2021) -
Update on the role of copanlisib in hematologic malignancies
por: Le, Thuy, et al.
Publicado: (2021) -
Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
por: Mensah, Felix A, et al.
Publicado: (2018) -
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
por: Cheson, Bruce D., et al.
Publicado: (2018) -
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
por: Krause, Günter, et al.
Publicado: (2018)